CORCEPT THERAPEUTICS INC (CORT) Quick Ratio
- Quick ratio · latest quarter: Value 2.50×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.50× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $385.12M ÷ $153.80M ≈ 2.50× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 385.12M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 153.80M USD | Liabilities, Current |
| Cash and equivalents | 111.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 197.16M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 76.92M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 13.19M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $385.12M | $153.80M | $111.04M | $197.16M | $76.92M | $13.19M | 2.50× |
| 2026-03-31 | $377.26M | $149.19M | $108.74M | $229.45M | $39.07M | $12.89M | 2.53× |
| 2025-12-31 | $431.94M | $166.09M | $120.50M | $251.66M | $59.79M | $12.87M | 2.60× |
| 2025-09-30 | $491.31M | $172.26M | $125.14M | $296.55M | $69.63M | $12.35M | 2.85× |
| 2025-06-30 | $406.79M | $144.66M | $102.75M | $239.48M | $64.57M | $12.28M | 2.81× |
| 2025-03-31 | $384.58M | $143.07M | $89.82M | $232.94M | $61.82M | $14.37M | 2.69× |
| 2024-12-31 | $437.31M | $140.77M | $127.67M | $255.67M | $53.98M | $12.41M | 3.11× |
| 2024-09-30 | $440.05M | $126.22M | $137.29M | $243.05M | $59.72M | $8.05M | 3.49× |
| 2024-06-30 | $526.99M | $100.75M | $128.59M | $344.57M | $53.84M | $8.35M | 5.23× |
| 2024-03-31 | $472.28M | $97.20M | $149.75M | $261.01M | $61.52M | $7.19M | 4.86× |
| 2023-12-31 | $409.34M | $104.50M | $135.55M | $232.67M | $41.12M | $7.73M | 3.92× |
| 2023-09-30 | $389.85M | $121.87M | $111.80M | $243.43M | $34.63M | $7.51M | 3.20× |
| 2023-06-30 | $395.81M | $93.06M | $172.38M | $190.88M | $32.55M | $6.92M | 4.25× |
| 2023-03-31 | $497.61M | $78.86M | $299.94M | $165.12M | $32.56M | $6.41M | 6.31× |
| 2022-12-31 | $462.73M | $72.49M | $66.33M | $365.34M | $31.06M | $6.10M | 6.38× |
| 2022-09-30 | (m) | $53.07M | (m) | $346.02M | $29.41M | $6.05M | (m) |
| 2022-06-30 | $398.25M | $49.06M | $35.35M | $334.74M | $28.16M | $5.44M | 8.12× |
| 2022-03-31 | $372.70M | $57.24M | $61.86M | $283.67M | $27.18M | $5.08M | 6.51× |
| 2021-12-31 | $251.16M | $47.54M | $77.62M | $145.92M | $27.63M | $4.99M | 5.28× |
| 2021-09-30 | $387.84M | $44.76M | $94.69M | $266.64M | $26.51M | $4.99M | 8.67× |
| 2021-06-30 | $397.60M | $45.40M | $95.43M | $274.55M | $27.62M | $4.67M | 8.76× |
| 2021-03-31 | $395.16M | $40.60M | $52.38M | $320.58M | $22.20M | $4.95M | 9.73× |
| 2020-12-31 | $466.89M | $47.49M | $76.19M | $364.51M | $26.20M | $4.91M | 9.83× |
| 2020-09-30 | $450.75M | $43.05M | $30.56M | $398.23M | $21.96M | $4.82M | 10.47× |
| 2020-06-30 | $428.08M | $42.24M | $58.52M | $346.83M | $22.73M | $4.93M | 10.13× |
| 2020-03-31 | $334.00M | $34.08M | $84.48M | $222.84M | $26.68M | $5.08M | 9.80× |
| 2019-12-31 | $295.89M | $38.84M | $31.27M | $244.69M | $19.93M | $5.42M | 7.62× |
| 2019-09-30 | $254.05M | $32.40M | $44.95M | $186.70M | $22.41M | $5.46M | 7.84× |
| 2019-06-30 | $221.31M | $30.38M | $58.14M | $143.40M | $19.77M | $5.14M | 7.28× |
| 2019-03-31 | $206.12M | $34.22M | $49.65M | $137.25M | $19.22M | $5.00M | 6.02× |
| 2018-12-31 | $224.35M | $35.57M | $41.63M | $165.13M | $17.59M | $4.73M | 6.31× |
| 2018-09-30 | $214.55M | $40.21M | $33.89M | $161.30M | $19.36M | $5.36M | 5.34× |
| 2018-06-30 | $188.65M | $30.87M | $31.16M | $128.78M | $28.70M | $4.95M | 6.11× |
| 2018-03-31 | $142.62M | $27.75M | $33.12M | $92.24M | $17.26M | $4.88M | 5.14× |
| 2017-12-31 | $104.04M | $29.57M | $31.06M | $57.68M | $15.30M | $4.58M | 3.52× |
| 2017-09-30 | $87.03M | $24.37M | $31.06M | $44.10M | $11.87M | $3.83M | 3.57× |
| 2017-06-30 | $75.67M | $20.39M | $33.62M | $32.54M | $9.50M | $3.09M | 3.71× |
| 2017-03-31 | $61.99M | $25.76M | $37.98M | $14.80M | $9.21M | $2.89M | 2.41× |
| 2016-12-31 | (m) | $27.37M | $51.54M | (m) | $9.86M | $2.33M | (m) |
| 2016-09-30 | (m) | $31.68M | $47.87M | (m) | $8.24M | $2.33M | (m) |
| 2016-06-30 | (m) | $27.43M | $41.79M | (m) | $9.30M | $2.13M | (m) |
| 2016-03-31 | (m) | $24.02M | $40.74M | (m) | $6.75M | $1.91M | (m) |
| 2015-12-31 | (m) | $20.88M | $40.44M | (m) | $6.22M | $1.68M | (m) |
| 2015-09-30 | (m) | $18.77M | $36.45M | (m) | $5.95M | $1.60M | (m) |
| 2015-06-30 | (m) | $17.43M | $37.05M | (m) | $4.95M | $1.45M | (m) |
| 2015-03-31 | (m) | $15.53M | $37.95M | (m) | $4.30M | $1.31M | (m) |
| 2014-12-31 | (m) | $13.55M | $24.25M | (m) | $3.33M | $1.21M | (m) |
| 2014-09-30 | (m) | $12.49M | $26.78M | (m) | $2.75M | $1.08M | (m) |
| 2014-06-30 | (m) | $13.30M | $33.97M | (m) | $2.23M | $1.07M | (m) |
| 2014-03-31 | (m) | $15.24M | $43.62M | (m) | $1.92M | $1.13M | (m) |
| 2013-12-31 | (m) | $12.74M | $54.88M | (m) | $1.43M | $1.10M | (m) |
| 2013-09-30 | (m) | $10.14M | $63.17M | (m) | $1.02M | $1.02M | (m) |
| 2013-06-30 | (m) | $9.08M | $72.22M | (m) | $855.00K | $694.00K | (m) |
| 2013-03-31 | (m) | $8.24M | $81.46M | (m) | $1.14M | $1.03M | (m) |
| 2012-12-31 | (m) | $8.36M | $93.03M | (m) | $557.00K | $853.00K | (m) |
| 2012-09-30 | (m) | $5.55M | $101.63M | (m) | $354.00K | $1.84M | (m) |
| 2012-06-30 | (m) | $5.82M | $34.90M | (m) | $355.00K | $2.44M | (m) |
| 2012-03-31 | (m) | $3.57M | $42.63M | (m) | (m) | $56.00K | (m) |
| 2011-12-31 | (m) | $5.03M | $39.63M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $2.71M | $45.91M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $3.86M | $52.23M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $59.20M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $3.86M | $24.58M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $28.98M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $35.38M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $23.87M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $14.72M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |